Understanding the interaction of hepatitis C virus with host DEAD-box RNA helicases

World Journal of Gastroenterology

Volumn 20, Issue 11, 2014, Pages 2913-2926

  Upadya, Megha Haridas ^a   Aweya, Jude Juventus ^a   Tan, Yee Joo ^b  

^a NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^b INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

Author keywords

Chronic hepatitis C; DEAD box helicases; Hepatitis C virus; Hepatitis C virus therapy; Hepatocellular carcinoma; Host factors

Indexed keywords

ALISPORIVIR; BOCEPREVIR; DEAD BOX PROTEIN; DEAD BOX PROTEIN 1; DEAD BOX PROTEIN 17; DEAD BOX PROTEIN 20; DEAD BOX PROTEIN 3; DEAD BOX PROTEIN 5; DEAD BOX PROTEIN 6; TELAPREVIR; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS RNA; ANTIVIRUS AGENT;

ARTICLE; GENE EXPRESSION; GENE SILENCING; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; LIFE CYCLE; LIVER CANCER; LIVER CELL CARCINOMA; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PROTEIN PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA METABOLISM; VIRUS GENOME; VIRUS REPLICATION; WESTERN BLOTTING; ANIMAL; CARCINOMA, HEPATOCELLULAR; ENZYMOLOGY; HEPACIVIRUS; HOST PATHOGEN INTERACTION; LIVER NEOPLASMS; METABOLISM; PHYSIOLOGY;

ANIMALS; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; DEAD-BOX RNA HELICASES; GENOME, VIRAL; HEPACIVIRUS; HEPATITIS C; HOST-PATHOGEN INTERACTIONS; HUMANS; LIVER NEOPLASMS; VIRAL PROTEINS;

EID: 84896474581     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i11.2913     Document Type: Article

References (108)

1. Schaefer EA, Chung RT. Anti-hepatitis C virus drugs in development. Gastroenterology 2012; 142: 1340-1350. e1 [PMID: 22537441 DOI: 10.1053/j.gastro.2012.02.015]
2. Joyce MA, Tyrrell DL. The cell biology of hepatitis C virus. Microbes Infect 2010; 12: 263-271 [PMID: 20080204 DOI: 10.1016/j.micinf.2009.12.012]
3. Macdonald A, Harris M. Hepatitis C virus NS5A: tales of a promiscuous protein. J Gen Virol 2004; 85: 2485-2502 [PMID: 15302943 DOI: 10.1099/vir.0.80204-0]
4. Tan SL, Pause A, Shi Y, Sonenberg N. Hepatitis C therapeutics: current status and emerging strategies. Nat Rev Drug Discov 2002; 1: 867-881 [PMID: 12415247 DOI: 10.1038/nrd937]
5. Simmonds P, Bukh J, Combet C, Deléage G, Enomoto N, Feinstone S, Halfon P, Inchauspé G, Kuiken C, Maertens G, Mizokami M, Murphy DG, Okamoto H, Pawlotsky JM, Penin F, Sablon E, Shin IT, Stuyver LJ, Thiel HJ, Viazov S, Weiner AJ, Widell A. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005; 42: 962-973 [PMID: 16149085 DOI: 10.1002/hep.20819]
6. Santantonio T, Sinisi E, Guastadisegni A, Casalino C, Mazzola M, Gentile A, Leandro G, Pastore G. Natural course of acute hepatitis C: a long-term prospective study. Dig Liver Dis 2003; 35: 104-113 [PMID: 12747629]
7. Swain MG, Lai MY, Shiffman ML, Cooksley WG, Zeuzem S, Dieterich DT, Abergel A, Pessôa MG, Lin A, Tietz A, Connell EV, Diago M. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology 2010; 139: 1593-1601 [PMID: 20637202 DOI: 10.1053/j.gastro.2010.07.009]
8. Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-355 [PMID: 14996676]
9. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982 [PMID: 12324553 DOI: 10.1056/NEJMoa020047]
10. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965 [PMID: 11583749]
11. Scheel TK, Rice CM. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat Med 2013; 19: 837-849 [PMID: 23836234 DOI: 10.1038/nm.3248]
12. Shah N, Pierce T, Kowdley KV. Review of direct-acting antiviral agents for the treatment of chronic hepatitis C. Expert Opin Investig Drugs 2013; 22: 1107-1121 [PMID: 23735127 DOI: 10.1517/13543784.2013.806482]
13. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-1217 [PMID: 21449784 DOI: 10.1056/NEJMoa1009482]
14. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245-264 [PMID: 21371579 DOI: 10.1016/j.jhep.2011.02.023]
15. Hézode C. Oral combination therapy: future hepatitis C virus treatment? J Hepatol 2011; 55: 933-935 [PMID: 21708200 DOI: 10.1016/j.jhep.2011.04.018]
16. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416 [PMID: 21696307 DOI: 10.1056/NEJMoa1012912]
17. Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206 [PMID: 21449783 DOI: 10.1056/NEJMoa1010494]
18. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Müllhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-2428 [PMID: 21696308 DOI: 10.1056/NEJMoa1013086]
19. Welsch C, Jesudian A, Zeuzem S, Jacobson I. New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives. Gut 2012; 61 Suppl 1: i36-i46 [PMID: 22504918 DOI: 10.1136/gutjnl-2012-302144]
20. Chatel-Chaix L, Germain MA, Götte M, Lamarre D. Direct-acting and host-targeting HCV inhibitors: current and future directions. Curr Opin Virol 2012; 2: 588-598 [PMID: 22959589 DOI: 10.1016/j.coviro.2012.08.002]
21. Pawlotsky JM. Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology 2011; 53: 1742-1751 [PMID: 21374691 DOI: 10.1002/hep.24262]
22. Aloia AL, Locarnini S, Beard MR. Antiviral resistance and direct-acting antiviral agents for HCV. Antivir Ther 2012; 17: 1147-1162 [PMID: 23188771 DOI: 10.3851/imp2426]
23. Huang Z, Murray MG, Secrist JA. Recent development of therapeutics for chronic HCV infection. Antiviral Res 2006; 71: 351-362 [PMID: 16828888 DOI: 10.1016/j.antiviral.2006.06.001]
24. Koev G, Kati W. The emerging field of HCV drug resistance. Expert Opin Investig Drugs 2008; 17: 303-319 [PMID: 18321230 DOI: 10.1517/13543784.17.3.303]
25. Einav S, Gerber D, Bryson PD, Sklan EH, Elazar M, Maerkl SJ, Glenn JS, Quake SR. Discovery of a hepatitis C target and its pharmacological inhibitors by microfluidic affinity analysis. Nat Biotechnol 2008; 26: 1019-1027 [PMID: 18758449 DOI: 10.1038/nbt.1490]
26. Pan Q, van der Laan LJ. New targets for treatment against HCV infection. Best Pract Res Clin Gastroenterol 2012; 26: 505-515 [PMID: 23199508 DOI: 10.1016/j.bpg.2012.10.002]
27. Bartenschlager R, Lohmann V. Replication of hepatitis C virus. J Gen Virol 2000; 81: 1631-1648 [PMID: 10859368]
28. Zeuzem S, Arora S, Bacon B, Box T, Charlton M, Diago M, Dieterich D, Esteban Mur R, Everson G, Fallon M, Ferenci P, Flisiak R, George J, Ghalib R, Gitlin N, Gladysz A, Gordon S, Greenbloom S, Hassanein T, Jacobson I, Jeffers L, Kowdley K, Lawitz E, Lee S, Leggett B, Lueth S, Nelson D, Pockros P, Rodriguez-Torres M, Rustgi V, Serfaty L, Sherman M, Shiffman M, Sola R, Sulkowski M, Vargas H, Vierling J, Yoffe B, Ishak L, Fontana D, Xu D, Lester J, Gray T, Horga A, Hillson J, Ramos E, Lopez-Talavera JC, Muir A. Pegylated interferon-lambda (PEGIFN-λ) shows superior viral response with improved safety and tolerability versus PEGIFNα-2A in HCV patients (Gl/2/3/4): EMERGE Phase IIB through week 12. J Hepatol 2011; 54: S538-S539 (abstract 1362)
29. Boonstra A, Liu BS, Groothuismink ZM, Bergmann JF, de Bruijne J, Hotho DM, Hansen BE, van Vliet AA, van de Wetering de Rooij J, Fletcher SP, Bauman LA, Rahimy M, Appleman JR, Freddo JL, Reesink HW, de Knegt RJ, Janssen HL. Potent immune activation in chronic hepatitis C patients upon administration of an oral inducer of endogenous interferons that acts via Toll-like receptor 7. Antivir Ther 2012; 17: 657-667 [PMID: 22301364 DOI: 10.3851/imp2023]
30. Zhang X, Kraft A, Broering R, Schlaak JF, Dittmer U, Lu M. Preclinical development of TLR ligands as drugs for the treatment of chronic viral infections. Expert Opin Drug Discov 2012; 7: 597-611 [PMID: 22607384 DOI: 10.1517/17460441.2012.689281]
31. Fafi-Kremer S, Fofana I, Soulier E, Carolla P, Meuleman P, Leroux-Roels G, Patel AH, Cosset FL, Pessaux P, Doffoël M, Wolf P, Stoll-Keller F, Baumert TF. Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation. J Exp Med 2010; 207: 2019-2031 [PMID: 20713596 DOI: 10.1084/jem.20090766]
32. Zeisel MB, Lupberger J, Fofana I, Baumert TF. Host-targeting agents for prevention and treatment of chronic hepatitis C-perspectives and challenges. J Hepatol 2013; 58: 375-384 [PMID: 23041307 DOI: 10.1016/j.jhep.2012.09.022]
33. Lupberger J, Zeisel MB, Xiao F, Thumann C, Fofana I, Zona L, Davis C, Mee CJ, Turek M, Gorke S, Royer C, Fischer B, Zahid MN, Lavillette D, Fresquet J, Cosset FL, Rothenberg SM, Pietschmann T, Patel AH, Pessaux P, Doffoël M, Raffelsberger W, Poch O, McKeating JA, Brino L, Baumert TF. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med 2011; 17: 589-595 [PMID: 21516087 DOI: 10.1038/nm.2341]
34. Zhu H, Wong-Staal F, Lee H, Syder A, McKelvy J, Schooley RT, Wyles DL. Evaluation of ITX 5061, a scavenger receptor B1 antagonist: resistance selection and activity in combination with other hepatitis C virus antivirals. J Infect Dis 2012; 205: 656-662 [PMID: 22279172 DOI: 10.1093/infdis/jir802]
35. von Hahn T, Ciesek S, Manns MP. Arrest all accessories--inhibition of hepatitis C virus by compounds that target host factors. Discov Med 2011; 12: 237-244 [PMID: 21955851]
36. Samreen B, Khaliq S, Ashfaq UA, Khan M, Afzal N, Shahzad MA, Riaz S, Jahan S. Hepatitis C virus entry: role of host and viral factors. Infect Genet Evol 2012; 12: 1699-1709 [PMID: 22878095 DOI: 10.1016/j.meegid.2012.07.010]
37. Pawlotsky JM. The science of direct-acting antiviral and host-targeted agent therapy. Antivir Ther 2012; 17: 1109-1117 [PMID: 23188746 DOI: 10.3851/imp2423]
38. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, Habermann A, Kräusslich HG, Mizokami M, Bartenschlager R, Liang TJ. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005; 11: 791-796 [PMID: 15951748 DOI: 10.1038/nm1268]
39. Lindenbach BD, Evans MJ, Syder AJ, Wölk B, Tellinghuisen TL, Liu CC, Maruyama T, Hynes RO, Burton DR, McKeating JA, Rice CM. Complete replication of hepatitis C virus in cell culture. Science 2005; 309: 623-626 [PMID: 15947137 DOI: 10.1126/science.1114016]
40. Rocak S, Linder P. DEAD-box proteins: the driving forces behind RNA metabolism. Nat Rev Mol Cell Biol 2004; 5: 232-241 [PMID: 14991003 DOI: 10.1038/nrm1335]
41. Story RM, Steitz TA. Structure of the recA protein-ADP complex. Nature 1992; 355: 374-376 [PMID: 1731253 DOI: 10.1038/355374a0]
42. Caruthers JM, Johnson ER, McKay DB. Crystal structure of yeast initiation factor 4A, a DEAD-box RNA helicase. Proc Natl Acad Sci USA 2000; 97: 13080-13085 [PMID: 11087862 DOI: 10.1073/pnas.97.24.13080]
43. Carmel AB, Matthews BW. Crystal structure of the BstDEAD N-terminal domain: a novel DEAD protein from Bacillus stearothermophilus. RNA 2004; 10: 66-74 [PMID: 14681586]
44. Seth RB, Sun L, Chen ZJ. Antiviral innate immunity pathways. Cell Res 2006; 16: 141-147 [PMID: 16474426 DOI: 10.1038/sj.cr.7310019]
45. Gerlier D, Lyles DS. Interplay between innate immunity and negative-strand RNA viruses: towards a rational model. Microbiol Mol Biol Rev 2011; 75: 468-490, second page of table of contents [PMID: 21885681 DOI: 10.1128/mmbr.00007-11]
46. Horner SM. Activation and Evasion of Antiviral Innate Immunity by Hepatitis C Virus. J Mol Biol 2014; 426: 1198-1209 [PMID: 24184198 DOI: 10.1016/j.jmb.2013.10.032]
47. Oshiumi H, Funami K, Aly HH, Matsumoto M, Seya T. Multi-step regulation of interferon induction by hepatitis C virus. Arch Immunol Ther Exp (Warsz) 2013; 61: 127-138 [PMID: 23292079 DOI: 10.1007/s00005-012-0214-x]
48. Tingting P, Caiyun F, Zhigang Y, Pengyuan Y, Zhenghong Y. Subproteomic analysis of the cellular proteins associated with the 3' untranslated region of the hepatitis C virus genome in human liver cells. Biochem Biophys Res Commun 2006; 347: 683-691 [PMID: 16842740 DOI: 10.1016/j.bbrc.2006.06.144]
49. Godbout R, Packer M, Bie W. Overexpression of a DEAD box protein (DDX1) in neuroblastoma and retinoblastoma cell lines. J Biol Chem 1998; 273: 21161-21168 [PMID: 9694872]
50. Fang J, Kubota S, Yang B, Zhou N, Zhang H, Godbout R, Pomerantz RJ. A DEAD box protein facilitates HIV-1 replication as a cellular co-factor of Rev. Virology 2004; 330: 471-480 [PMID: 15567440 DOI: 10.1016/j.virol.2004.09.039]
51. Borgia G, Reynaud L, Gentile I, Piazza M. HIV and hepatitis C virus: facts and controversies. Infection 2003; 31: 232-240 [PMID: 14562947]
52. Tan YJ, Lim SG, Hong W. Understanding human immunodeficiency virus type 1 and hepatitis C virus coinfection. Curr HIV Res 2006; 4: 21-30 [PMID: 16454708]
53. Schröder M. Human DEAD-box protein 3 has multiple functions in gene regulation and cell cycle control and is a prime target for viral manipulation. Biochem Pharmacol 2010; 79: 297-306 [PMID: 19782656 DOI: 10.1016/j.bcp.2009.08.032]
54. Schröder M, Baran M, Bowie AG. Viral targeting of DEAD box protein 3 reveals its role in TBK1/IKKepsilon-mediated IRF activation. EMBO J 2008; 27: 2147-2157 [PMID: 18636090 DOI: 10.1038/emboj.2008.143]
55. Soulat D, Bürckstümmer T, Westermayer S, Goncalves A, Bauch A, Stefanovic A, Hantschel O, Bennett KL, Decker T, Superti-Furga G. The DEAD-box helicase DDX3X is a critical component of the TANK-binding kinase 1-dependent innate immune response. EMBO J 2008; 27: 2135-2146 [PMID: 18583960 DOI: 10.1038/emboj.2008.126]
56. Cheng G, Zhong J, Chisari FV. Inhibition of dsRNA-induced signaling in hepatitis C virus-infected cells by NS3 protease-dependent and-independent mechanisms. Proc Natl Acad Sci USA 2006; 103: 8499-8504 [PMID: 16707574 DOI: 10.1073/pnas.0602957103]
57. Kawai T, Akira S. The roles of TLRs, RLRs and NLRs in pathogen recognition. Int Immunol 2009; 21: 317-337 [PMID: 19246554 DOI: 10.1093/intimm/dxp017]
58. Oshiumi H, Sakai K, Matsumoto M, Seya T. DEAD/H BOX 3 (DDX3) helicase binds the RIG-I adaptor IPS-1 to up-regulate IFN-beta-inducing potential. Eur J Immunol 2010; 40: 940-948 [PMID: 20127681 DOI: 10.1002/eji.200940203]
59. Ariumi Y, Kuroki M, Abe K, Dansako H, Ikeda M, Wakita T, Kato N. DDX3 DEAD-box RNA helicase is required for hepatitis C virus RNA replication. J Virol 2007; 81: 13922-13926 [PMID: 17855521 DOI: 10.1128/jvi.01517-07]
60. Randall G, Panis M, Cooper JD, Tellinghuisen TL, Sukhodolets KE, Pfeffer S, Landthaler M, Landgraf P, Kan S, Lindenbach BD, Chien M, Weir DB, Russo JJ, Ju J, Brownstein MJ, Sheridan R, Sander C, Zavolan M, Tuschl T, Rice CM. Cellular cofactors affecting hepatitis C virus infection and replication. Proc Natl Acad Sci USA 2007; 104: 12884-12889 [PMID: 17616579 DOI: 10.1073/pnas.0704894104]
61. Yedavalli VS, Neuveut C, Chi YH, Kleiman L, Jeang KT. Requirement of DDX3 DEAD box RNA helicase for HIV-1 Rev-RRE export function. Cell 2004; 119: 381-392 [PMID: 15507209 DOI: 10.1016/j.cell.2004.09.029]
62. Schröder M. Viruses and the human DEAD-box helicase DDX3: inhibition or exploitation? Biochem Soc Trans 2011; 39: 679-683 [PMID: 21428961 DOI: 10.1042/bst0390679]
63. Mamiya N, Worman HJ. Hepatitis C virus core protein binds to a DEAD box RNA helicase. J Biol Chem 1999; 274: 15751-15756 [PMID: 10336476]
64. Owsianka AM, Patel AH. Hepatitis C virus core protein interacts with a human DEAD box protein DDX3. Virology 1999; 257: 330-340 [PMID: 10329544 DOI: 10.1006/viro.1999.9659]
65. You LR, Chen CM, Yeh TS, Tsai TY, Mai RT, Lin CH, Lee YH. Hepatitis C virus core protein interacts with cellular putative RNA helicase. J Virol 1999; 73: 2841-2853 [PMID: 10074132]
66. Angus AG, Dalrymple D, Boulant S, McGivern DR, Clayton RF, Scott MJ, Adair R, Graham S, Owsianka AM, Targett-Adams P, Li K, Wakita T, McLauchlan J, Lemon SM, Patel AH. Requirement of cellular DDX3 for hepatitis C virus replication is unrelated to its interaction with the viral core protein. J Gen Virol 2010; 91: 122-132 [PMID: 19793905 DOI: 10.1099/vir.0.015909-0]
67. Sun C, Pager CT, Luo G, Sarnow P, Cate JH. Hepatitis C virus core-derived peptides inhibit genotype 1b viral genome replication via interaction with DDX3X. PLoS One 2010; 5: [PMID: 20862261 DOI: 10.1371/journal.pone.0012826]
68. Goh PY, Tan YJ, Lim SP, Tan YH, Lim SG, Fuller-Pace F, Hong W. Cellular RNA helicase p68 relocalization and interaction with the hepatitis C virus (HCV) NS5B protein and the potential role of p68 in HCV RNA replication. J Virol 2004; 78: 5288-5298 [PMID: 15113910]
69. McGivern DR, Lemon SM. Virus-specific mechanisms of carcinogenesis in hepatitis C virus associated liver cancer. Oncogene 2011; 30: 1969-1983 [PMID: 21258404 DOI: 10.1038/onc.2010.594]
70. Dutta S, Gupta G, Choi YW, Kotaka M, Fielding BC, Song J, Tan YJ. The variable N-terminal region of DDX5 contains structural elements and auto-inhibits its interaction with NS5B of hepatitis C virus. Biochem J 2012; 446: 37-46 [PMID: 22640416 DOI: 10.1042/bj20120001]
71. Lim SP, Soo HM, Tan YH, Brenner S, Horstmann H, MacKenzie JM, Ng ML, Lim SG, Hong WJ. Inducible system in human hepatoma cell lines for hepatitis C virus production. Virology 2002; 303: 79-99 [PMID: 12482660]
72. Bungyoku Y, Shoji I, Makine T, Adachi T, Hayashida K, Nagano-Fujii M, Ide YH, Deng L, Hotta H. Efficient production of infectious hepatitis C virus with adaptive mutations in cultured hepatoma cells. J Gen Virol 2009; 90: 1681-1691 [PMID: 19282429 DOI: 10.1099/vir.0.010983-0]
73. Mohd-Ismail NK, Deng L, Sukumaran SK, Yu VC, Hotta H, Tan YJ. The hepatitis C virus core protein contains a BH3 domain that regulates apoptosis through specific interaction with human Mcl-1. J Virol 2009; 83: 9993-10006 [PMID: 19605477 DOI: 10.1128/jvi.00509-09]
74. Deng L, Adachi T, Kitayama K, Bungyoku Y, Kitazawa S, Ishido S, Shoji I, Hotta H. Hepatitis C virus infection induces apoptosis through a Bax-triggered, mitochondrion-mediated, caspase 3-dependent pathway. J Virol 2008; 82: 10375-10385 [PMID: 18768989 DOI: 10.1128/jvi.00395-08]
75. Kuroki M, Ariumi Y, Hijikata M, Ikeda M, Dansako H, Wakita T, Shimotohno K, Kato N. PML tumor suppressor protein is required for HCV production. Biochem Biophys Res Commun 2013; 430: 592-597 [PMID: 23219818 DOI: 10.1016/j.bbrc.2012.11.108]
76. Ariumi Y, Kuroki M, Maki M, Ikeda M, Dansako H, Wakita T, Kato N. The ESCRT system is required for hepatitis C virus production. PLoS One 2011; 6: e14517 [PMID: 21264300 DOI: 10.1371/journal.pone.0014517]
77. Huang H, Shiffman ML, Cheung RC, Layden TJ, Friedman S, Abar OT, Yee L, Chokkalingam AP, Schrodi SJ, Chan J, Catanese JJ, Leong DU, Ross D, Hu X, Monto A, McAllister LB, Broder S, White T, Sninsky JJ, Wright TL. Identification of two gene variants associated with risk of advanced fibrosis in patients with chronic hepatitis C. Gastroenterology 2006; 130: 1679-1687 [PMID: 16697732 DOI: 10.1053/j.gastro.2006.02.032]
78. Scheller N, Mina LB, Galão RP, Chari A, Giménez-Barcons M, Noueiry A, Fischer U, Meyerhans A, Díez J. Translation and replication of hepatitis C virus genomic RNA depends on ancient cellular proteins that control mRNA fates. Proc Natl Acad Sci USA 2009; 106: 13517-13522 [PMID: 19628699 DOI: 10.1073/pnas.0906413106]
79. Jangra RK, Yi M, Lemon SM. DDX6 (Rck/p54) is required for efficient hepatitis C virus replication but not for internal ribosome entry site-directed translation. J Virol 2010; 84: 6810-6824 [PMID: 20392846 DOI: 10.1128/jvi.00397-10]
80. Pager CT, Schütz S, Abraham TM, Luo G, Sarnow P. Modulation of hepatitis C virus RNA abundance and virus release by dispersion of processing bodies and enrichment of stress granules. Virology 2013; 435: 472-484 [PMID: 23141719 DOI: 10.1016/j.virol.2012.10.027]
81. Huys A, Thibault PA, Wilson JA. Modulation of hepatitis C virus RNA accumulation and translation by DDX6 and miR-122 are mediated by separate mechanisms. PLoS One 2013; 8: e67437 [PMID: 23826300 DOI: 10.1371/journal.pone.0067437]
82. Jin DY. Molecular pathogenesis of hepatitis C virus-associated hepatocellular carcinoma. Front Biosci 2007; 12: 222-233 [PMID: 17127295]
83. Jeong SW, Jang JY, Chung RT. Hepatitis C virus and hepatocarcinogenesis. Clin Mol Hepatol 2012; 18: 347-356 [PMID: 23323249 DOI: 10.3350/cmh.2012.18.4.347]
84. Arzumanyan A, Reis HM, Feitelson MA. Pathogenic mechanisms in HBV-and HCV-associated hepatocellular carcinoma. Nat Rev Cancer 2013; 13: 123-135 [PMID: 23344543 DOI: 10.1038/nrc3449]
85. Fuller-Pace FV, Moore HC. RNA helicases p68 and p72: multifunctional proteins with important implications for cancer development. Future Oncol 2011; 7: 239-251 [PMID: 21345143 DOI: 10.2217/fon.11.1]
86. Kitagawa N, Ojima H, Shirakihara T, Shimizu H, Kokubu A, Urushidate T, Totoki Y, Kosuge T, Miyagawa S, Shibata T. Downregulation of the microRNA biogenesis components and its association with poor prognosis in hepatocellular carcinoma. Cancer Sci 2013; 104: 543-551 [PMID: 23398123 DOI: 10.1111/cas.12126]
87. Sekine S, Ogawa R, Ito R, Hiraoka N, McManus MT, Kanai Y, Hebrok M. Disruption of Dicer1 induces dysregulated fetal gene expression and promotes hepatocarcinogenesis. Gastroenterology 2009; 136: 2304-2315. e1-4 [PMID: 19272382 DOI: 10.1053/j.gastro.2009.02.067]
88. Miyaji K, Nakagawa Y, Matsumoto K, Yoshida H, Morikawa H, Hongou Y, Arisaka Y, Kojima H, Inoue T, Hirata I, Katsu K, Akao Y. Overexpression of a DEAD box/RNA helicase protein, rck/p54, in human hepatocytes from patients with hepatitis C virus-related chronic hepatitis and its implication in hepatocellular carcinogenesis. J Viral Hepat 2003; 10: 241-248 [PMID: 12823589]
89. Chu CY, Rana TM. Translation repression in human cells by microRNA-induced gene silencing requires RCK/p54. PLoS Biol 2006; 4: e210 [PMID: 16756390 DOI: 10.1371/journal.pbio.0040210]
90. Mourelatos Z, Dostie J, Paushkin S, Sharma A, Charroux B, Abel L, Rappsilber J, Mann M, Dreyfuss G. miRNPs: a novel class of ribonucleoproteins containing numerous microRNAs. Genes Dev 2002; 16: 720-728 [PMID: 11914277 DOI: 10.1101/gad.974702]
91. Hutvágner G, Zamore PD. A microRNA in a multiple-turnover RNAi enzyme complex. Science 2002; 297: 2056-2060 [PMID: 12154197 DOI: 10.1126/science.1073827]
92. Zender L, Xue W, Zuber J, Semighini CP, Krasnitz A, Ma B, Zender P, Kubicka S, Luk JM, Schirmacher P, McCombie WR, Wigler M, Hicks J, Hannon GJ, Powers S, Lowe SW. An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell 2008; 135: 852-864 [PMID: 19012953 DOI: 10.1016/j.cell.2008.09.061]
93. Takata A, Otsuka M, Yoshikawa T, Kishikawa T, Kudo Y, Goto T, Yoshida H, Koike K. A miRNA machinery component DDX20 controls NF-κB via microRNA-140 function. Biochem Biophys Res Commun 2012; 420: 564-569 [PMID: 22445758 DOI: 10.1016/j.bbrc.2012.03.034]
94. Takata A, Otsuka M, Yoshikawa T, Kishikawa T, Hikiba Y, Obi S, Goto T, Kang YJ, Maeda S, Yoshida H, Omata M, Asahara H, Koike K. MicroRNA-140 acts as a liver tumor suppressor by controlling NF-κB activity by directly targeting DNA methyltransferase 1 (Dnmt1) expression. Hepatology 2013; 57: 162-170 [PMID: 22898998 DOI: 10.1002/hep.26011]
95. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006; 441: 431-436 [PMID: 16724054 DOI: 10.1038/nature04870]
96. Luedde T, Schwabe RF. NF-κB in the liver--linking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2011; 8: 108-118 [PMID: 21293511 DOI: 10.1038/nrgastro.2010.213]
97. Huang JS, Chao CC, Su TL, Yeh SH, Chen DS, Chen CT, Chen PJ, Jou YS. Diverse cellular transformation capability of overexpressed genes in human hepatocellular carcinoma. Biochem Biophys Res Commun 2004; 315: 950-958 [PMID: 14985104 DOI: 10.1016/j.bbrc.2004.01.151]
98. Li L, Chen SH, Yu CH, Li YM, Wang SQ. Identification of hepatocellular-carcinoma-associated antigens and autoantibodies by serological proteome analysis combined with protein microarray. J Proteome Res 2008; 7: 611-620 [PMID: 18161940 DOI: 10.1021/pr070525r]
99. Liu H, Zhang J, Wang S, Pang Z, Wang Z, Zhou W, Wu M. Screening of autoantibodies as potential biomarkers for hepatocellular carcinoma by using T7 phase display system. Cancer Epidemiol 2012; 36: 82-88 [PMID: 22018955 DOI: 10.1016/j.canep.2011.04.001]
100. Chang PC, Chi CW, Chau GY, Li FY, Tsai YH, Wu JC, Wu Lee YH. DDX3, a DEAD box RNA helicase, is deregulated in hepatitis virus-associated hepatocellular carcinoma and is involved in cell growth control. Oncogene 2006; 25: 1991-2003 [PMID: 16301996 DOI: 10.1038/sj.onc.1209239]
101. Chao CH, Chen CM, Cheng PL, Shih JW, Tsou AP, Lee YH. DDX3, a DEAD box RNA helicase with tumor growth-suppressive property and transcriptional regulation activity of the p21waf1/cip1 promoter, is a candidate tumor suppressor. Cancer Res 2006; 66: 6579-6588 [PMID: 16818630 DOI: 10.1158/0008-5472.can-05-2415]
102. Jansson MD, Lund AH. MicroRNA and cancer. Mol Oncol 2012; 6: 590-610 [PMID: 23102669 DOI: 10.1016/j.molonc.2012.09.006]
103. Farazi TA, Hoell JI, Morozov P, Tuschl T. MicroRNAs in human cancer. Adv Exp Med Biol 2013; 774: 1-20 [PMID: 23377965 DOI: 10.1007/978-94-007-5590-1_1]
104. Choi YJ, Lee SG. The DEAD-box RNA helicase DDX3 interacts with DDX5, co-localizes with it in the cytoplasm during the G2/M phase of the cycle, and affects its shuttling during mRNP export. J Cell Biochem 2012; 113: 985-996 [PMID: 22034099 DOI: 10.1002/jcb.23428]
105. Mailly L, Robinet E, Meuleman P, Baumert TF, Zeisel MB. Hepatitis C virus infection and related liver disease: the quest for the best animal model. Front Microbiol 2013; 4: 213 [PMID: 23898329 DOI: 10.3389/fmicb.2013.00212]
106. Billerbeck E, de Jong Y, Dorner M, de la Fuente C, Ploss A. Animal models for hepatitis C. Curr Top Microbiol Immunol 2013; 369: 49-86 [PMID: 23463197 DOI: 10.1007/978-3-642-27340-7_3]
107. Washburn ML, Bility MT, Zhang L, Kovalev GI, Buntzman A, Frelinger JA, Barry W, Ploss A, Rice CM, Su L. A humanized mouse model to study hepatitis C virus infection, immune response, and liver disease. Gastroenterology 2011; 140: 1334-1344 [PMID: 21237170 DOI: 10.1053/j.gastro.2011.01.001]
108. Dorner M, Horwitz JA, Donovan BM, Labitt RN, Budell WC, Friling T, Vogt A, Catanese MT, Satoh T, Kawai T, Akira S, Law M, Rice CM, Ploss A. Completion of the entire hepatitis C virus life cycle in genetically humanized mice. Nature 2013; 501: 237-241 [PMID: 23903655 DOI: 10.1038/nature12427]